Publications & Scientific Presentations
Lutz E, Rudraraju L, DeOliveira E, et al. Marrow-infiltrating lymphocytes (MILs): A novel adoptive immunotherapy for hematological and solid tumors. Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-SITC2020.0154.
Lutz E, Rudraraju L, DeOliveira E, et al. CAR T-engineered Marrow-infiltrating Lymphocytes (MILs™) are more polyfunctional than their matched peripheral blood counterparts. SITC 2019.
Biavati L., K. A. Noonan, L. Luznik, I. M. Borrello. Activated Allogeneic Donor-derived Marrow-infiltrating Lymphocytes Display Measurable In Vitro Antitumor Activity. J Immunother. 2019 Apr;42(3):73-80.
Lutz, E. R., V. Hoyos, L. Rudraraju, E. DeOliveira, S. Jana, I. Weiss, I. M. Borrello and K. A. Noonan. Marrow-Infiltrating Lymphocytes (MILs) Provide a Robust Platform for CAR-T Cell Therapy. 2018 Blood 132:3337.
Lutz, E. R., A. Hopkins, L. Radraraju, E. DeOlivera, I. Weiss, R. Gittelman, E. Yusko, K. G. Boland, I. M. Borrello and K. A. Noonan. T-cell receptor (TCR) repertoire features associated with disease-free survival following infusion with marrow-infiltrating lymphocytes (MILs). Poster presented at SITC 2018, Society for Immunotherapy of Cancer; Nov 9-10, 2018; Washington, D.C.
Lutz, E. R., L. Rudraraju, E. DeOliveria, W. N. Brennen, E. Efstatihiou, I. M. Borrello and K. A. Noonan. Marrow Infiltrating Lymphocytes (MILs): a Novel Adoptive Immunotherapy Approach for Metastatic Prostate Cancer Shows Measurable Tumor Specificity. Poster presented at ASGCT 2018, American Society of Gene and Cell Therapy; May 16, 2018; Chicago.
Noonan, K. A. and I. M. Borrello. Marrow-Infiltrating Lymphocytes – Role in Biology and Cancer Therapy. 2016. Front. Immunol. 7:112.
Noonan, K. A., L. Rudraraju, V. Hoyos, E. Lutz and I. Borrello. Persistence of Non Gene-Modified Adoptively Transferred Marrow Infiltrating Lymphocytes (MILs) More Than Five Years Post Transfer. 2016. Blood. 128(22):4552.
Noonan, K. A., C. A. Huff, J. Davis, M. V. Lemas, S. Fiorino, J. Bitzan, A. Ferguson, A. Emerling, L. Luznik, W. Matsui, J. Powell, E. Fuchs, G. L. Rosner, C. Epstein, L. Rudraraju, R. F. Ambinder, R. J. Jones, D. Pardoll and I. Borrello. Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. 2015. Science translational medicine. 7(288):288ra278-288ra278.
Noonan, K. A. and I. M. Borrello. Marrow Infiltrating Lymphocytes: Their Role in Adoptive Immunotherapy. 2015. Cancer J. 21(6):501-505.
Noonan, K., L. Rudraraju, A. Ferguson, A. Emerling, M. F. Pasetti, C. A. Huff and I. Borrello. Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses. 2012. Clin Cancer Res. 18(5):1426-1434.
Noonan, K. A., A. Ferguson, C. A. Huff, A. Emerling, S. Mgebroff, R. Wilson, R. D. Knight and I. M. Borrello. The Immunomodulatory Role of Lenalidomide on Prevnar® Responses in Patients with Relapsed Multiple Myeloma: A Comprehensive Analysis of the Immune Response. 2008. Blood. 112(11):2772.
Noonan, K., W. Matsui, P. Serafini, R. Carbley, G. Tan, J. Khalili, M. Bonyhadi, H. Levitsky, K. Whartenby and I. Borrello. Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. 2005. Cancer research. 65(5):2026-2034.